What’s the latest news on Ocriplasmin in 2025?

Ocriplasmin (Ocriplasmin) is a recombinant protease used to treat patients with vitreomacular traction (VMT) and with or without macular holes (MH). Its mechanism of action is based on selective cleavage of proteins in the vitreous-retinal interface, thereby relieving retinal traction pressure and improving macular morphology and visual function. In 2025, there will be new developments and observations of Ocriplasmin in clinical research and practical applications. The latest research has further clarified the importance of patient screening criteria, and imaging evaluation has become the key to judging efficacy. Optical coherence tomography (OCT) can accurately display the degree of vitreous traction and macular structural integrity, which is crucial for selecting patients suitable for Ocriplasmin injection, especially in individuals with mild to moderate traction, where the effect is most significant.

Data show that for patients with mild to moderate vitreomacular traction, a single intravitreal injection of Oakplasmin can improve the macular structure within a few weeks, and some patients can successfully relieve macular traction, thereby avoiding surgical intervention. The study also pointed out that patient age, traction area, macular hole diameter and vitreous transparency are important factors affecting the success rate of injection. Clinical observations in 2025 show that Ocriplasmin has a good overall safety profile. The most common adverse reactions are short-term blurred vision, mild eye pain, eye congestion, or increased floaters. These reactions usually resolve within a few days. Compared with traditional surgery, Ocriplasmin offers the possibility of non-invasive treatment, allowing patients to achieve therapeutic results while reducing surgical risks.

In addition, formulation optimization and delivery technology are also being continuously explored. For example, improved injection formulations and combined with image guidance technology can improve the uniform distribution and stability of drugs within the vitreous, thereby improving efficacy and reducing the risk of local complications. These innovations will not only help improve the success rate of a single injection, but may also expand the application prospects of Ocriplasmin in other vitreous diseases.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html